𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect

✍ Scribed by Eun J. Kim; Soo K. Bae; Hee J. Kim; Yoon G. Kim; Sun-O. Kim; Dong H. Lee; Hong Lim; Myung G. Lee


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
141 KB
Volume
92
Category
Article
ISSN
0022-3549

No coin nor oath required. For personal study only.

✦ Synopsis


Dose-independent pharmacokinetic parameters of SR-4668 were observed after intravenous (i.v.) administrations at doses of 25, 50, and 75 mg/kg and oral administrations at doses of 50, 100, and 150 mg/kg to rats. The hepatic, gastric, and intestinal first-pass effects of SR-4668 were also measured after i.v., intraportal (i.p.), intraduodenal (i.d.), and intragastric (i.g.) administrations at a dose of 50 mg/kg to rats. Although a considerable amount of orally administered SR-4668 was absorbed, the F was low--only 33%. This indicates considerable first-pass (gastric, intestinal, and/or hepatic) effects of SR-4668 in rats. After i.v. administrations, the total body clearances of SR-4668 were considerably slower than the reported cardiac output in rats, suggesting that the first-pass effects of SR-4668 in the lung and heart could be negligible, if any, in rats. The AUCs of SR-4668 were comparable between i.v. and i.p. administrations, suggesting that the hepatic first-pass effect of SR-4668 was not considerable in rats. The AUCs were also comparable between i.d. and i.g. administrations, suggesting that gastric first-pass effect was almost negligible in rats. However, the AUC after an i.d. administration was significantly smaller (approximately 55% decrease) than that after an i.p. administration, suggesting that the intestinal first-pass effect was approximately 55% of oral dose. The rests of the orally administered dose could be mainly due to degradation of SR-4668 in gastric juices; 77.3-95.6% of the spiked amount of SR-4668 were recovered after 4-h incubation in five human gastric juices. The above data suggested that the low F of SR-4668 could be mainly due to considerable intestinal first-pass effect in rats.


πŸ“œ SIMILAR VOLUMES


Dose-independent pharmacokinetics of a n
✍ Mi H. Lee; Soo K. Bae; Eun J. Kim; Yoon G. Kim; Sun-O. Kim; Dong H. Lee; Hong Li πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 147 KB

The purpose of this study was to report dose-independent pharmacokinetics of KR-31543, a new neuroprotective agent for ischemia-reperfusion damage, after intravenous (iv) and oral (po) administration and first-pass effects after iv, intraportal, intragastric, and intraduodenal administration in rats

Dose-independent pharmacokinetics of a n
✍ Su Yeon Yu; Soo Kyung Bae; Eun Jung Kim; Yoon Gyoon Kim; Sun-Ok Kim; Dong Ha Lee πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 142 KB

Dose-independent pharmacokinetic parameters of KR-60436, a new proton pump inhibitor, were evaluated after intravenous (i.v.; 5, 10, and 20 mg/kg) and oral (20, 50, and 100 mg/kg) administration to rats. The hepatic, gastric, and intestinal first-pass effects were also measured after iv, intraportal

Pharmacokinetics of DA-8159, a new erect
✍ Hyun J. Shim; Yu C. Kim; Kyung J. Park; Dong S. Kim; Jong W. Kwon; Won B. Kim; M πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 136 KB

The purposes of this study were to report dose-independent (after intravenous administration) and dose-dependent (after oral administration) area under the curve of plasma concentration versus time from time zero to time infinity (AUC), and gastric, intestinal, and/or hepatic first-pass effects (aft

Pharmacokinetics of L-FMAUS, a new antiv
✍ Hye J. Chung; Joo H. Lee; Sung J. Woo; Hee K. Park; Chang H. Koo; Myung G. Lee πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 167 KB πŸ‘ 2 views

## Abstract The pharmacokinetics of L‐FMAUS after intravenous and oral administration (20, 50 and 100 mg/kg) to rats, gastrointestinal first‐pass effect of L‐FMAUS (50 mg/kg) in rats, __in vitro__ stability of L‐FMAUS, blood partition of L‐FMAUS between plasma and blood cells of rat blood, and prot

Pharmacokinetics of a new reversible pro
✍ Kye S. Han; Yoon G. Kim; Joong K. Yoo; Jong W. Lee; Myung G. Lee πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 175 KB πŸ‘ 1 views

The pharmacokinetics of YH1885 were evaluated after intravenous (iv) and oral administrations of the drug to rats and dogs. The reason for the low extent of bioavailability (F) of YH1885 after oral administration of the drug to rats and the absorption of the drug from various rat gastrointestinal (G